MedTrace Logo

Cell Therapy With Bone Marrow Mononuclear Cells in Critical Leg Ischemia (CLI)

NCT00377897 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2009-02-16

No results posted yet for this study

Summary

This study will treat by cell therapy 20 patients with critical leg ischemia (CLI) not eligible for revascularization or angioplasty. It will use exactly the same protocol as published by Tateishi-Yuyama et al. (Lancet 2002), using bone-marrow mononuclear cells (BMMNC).

Conditions

  • Critical Leg Ischemia

Interventions

PROCEDURE

cell therapy

Injection of Bone-Marrow mononuclear cells in the muscles of the calf.

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    collaborator OTHER

  • University of Paris 5 - Rene Descartes

    lead OTHER

Principal Investigators

  • Joseph Emmerich · Assistance Publique - Hôpitaux de Paris

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2008-09-30
Completion
2009-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00377897 on ClinicalTrials.gov